Virus-like particles containing toxoplasma proteins and influenza virus proteins and diagnostic methods using the same
Virus-like particles containing Toxoplasma and influenza proteins provide a rapid and economical method for simultaneous diagnosis of both infections, addressing the limitations of conventional diagnostic methods by enhancing sensitivity and specificity.
Patent Information
- Application Number
- JP2023544409
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-01-22
- Filing Date
- 2021-12-06
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2041-12-06
AI Technical Summary
Conventional diagnostic methods for Toxoplasma gondii and influenza virus infections suffer from poor diagnostic speed, high costs, and low sensitivity, leading to confusion with other diseases due to similar symptoms.
Development of virus-like particles (VLPs) comprising surface antigen proteins from Toxoplasma gondii and influenza virus matrix protein 1 (M1) for multiplex diagnosis, utilizing genetic engineering to produce VLPs that react specifically with autoantibodies in infected individuals.
The VLPs demonstrate high specificity and sensitivity in detecting antibodies for both Toxoplasma gondii and influenza virus infections, enabling rapid and economical simultaneous diagnosis.
Smart Images

Figure 0007582716000001 
Figure 0007582716000002 
Figure 0007582716000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition and kit for diagnosing Toxoplasma and / or influenza virus, which comprises a virus-like particle containing Toxoplasma proteins and influenza virus proteins, and a method for diagnosing the presence or absence of Toxoplasma and / or influenza virus infection using the same. [Background technology]
[0002] Toxoplasma gondii is an intracellular parasite and a protozoan responsible for causing toxoplasmosis in humans and animals (Astrid M. Tenter et al.). Toxoplasma has five major developmental stages: oocyst, tachyzoite, bradyzoite, schizont, and gametocyte. Toxoplasma can be transmitted by ingesting water or vegetables contaminated by oocysts from the feces of cats, which are the definitive host, or by ingesting Toxoplasma that exists as cysts in the meat of intermediate hosts such as pigs, sheep, and cattle. It is estimated that more than one-third of the world's population is infected with Toxoplasma gondii, and in Japan, infection rates have been reported to range from 2 to 25% depending on the group.
[0003] In particular, when Toxoplasma infects a mother, its trophozoites can infect the fetus through the placenta. Toxoplasma infection can lead to miscarriage or stillbirth in early fetuses, and can cause congenital malformations such as visual impairment, hydrocephalus, and mental retardation in mid- to late-stage fetuses despite normal delivery. Toxoplasma that infects healthy individuals can also induce diseases such as lymphadenitis, retinal choroiditis, and encephalomyelitis by destroying immune system cells and reticular endothelial cells, and can cause meningitis or retinal choroiditis by activating cysts that have proliferated in the brain when the host's immune system is insufficient.
[0004] Meanwhile, influenza is one of the leading causes of human deaths from respiratory viruses. Common symptoms include fever, sore throat, difficulty breathing, and muscle pain, among others. Influenza viruses are highly contagious during influenza season, infecting 10% to 20% of the world's population and causing 250,000 to 500,000 deaths per year. What these diseases have in common is that they share similar symptoms to other diseases. Therefore, to reduce confusion with other diseases, various diagnostic methods are used, including immunological methods such as latex agglutination tests and antiserum diagnostic methods (enzyme-linked immunosorbent assay, enzyme-linked immunospecific assay, ELISA), and DNA detection methods such as nested PCR and real-time PCR.
[0005] However, conventional diagnostic methods have problems such as poor speed of diagnosis, low cost due to the use of expensive equipment, or low sensitivity, and therefore new diagnostic methods that are rapid, cost-effective, and highly sensitive are needed.
[0006] [Prior art document]
[0007] [Non-patent literature]
[0008] (Non-Patent Document 1) Astrid M.Tenter et al., "Toxoplasma gondii: from animals to humans", Int J Parasitol.2000 Nov;30(12-13), 1217-1258 Summary of the Invention [Problem to be solved by the invention]
[0009] In this regard, the present inventors conducted research to develop a method that can diagnose not only Toxoplasma with high sensitivity but also influenza virus simultaneously, while being rapid and cost-effective. As a result, they confirmed that a diagnostic method and diagnostic kit comprising the diagnostic composition in the form of a VLP according to the present invention have superior immunological specificity and sensitivity compared to antigen lysate and antigen protein, thereby completing the present invention. [Means for solving the problem]
[0010] To achieve the above object, a composition for multiple diagnosis of toxoplasmosis and / or influenza virus is provided, which comprises a virus-like particle comprising a surface antigen protein derived from Toxoplasma and influenza virus matrix protein 1 (M1).
[0011] In another aspect, the present invention provides a toxoplasmosis and / or influenza virus multiple diagnosis kit comprising the above-mentioned composition for multiple diagnosis of toxoplasmosis and / or influenza virus.
[0012] In another aspect of the present invention, there is provided a method for providing information necessary for multiplex diagnosis of Toxoplasma and / or influenza virus infection, comprising the steps of contacting a biological sample isolated from an individual with a toxoplasmosis and / or influenza virus multiple diagnostic composition comprising a virus-like particle comprising a surface antigen protein derived from Toxoplasma and influenza virus matrix protein 1, and detecting antibodies that bind to the virus-like particle. Effect of the Invention
[0013] The diagnostic composition comprising the virus-like particle containing the Toxoplasma antigen protein and the influenza virus M1 protein according to the present invention can react with autoantibodies present in the serum of individuals infected with Toxoplasma with high specificity and sensitivity, as well as with autoantibodies present in individuals infected with influenza virus. Therefore, the virus-like particle can be usefully used for Toxoplasma diagnosis and / or influenza virus diagnosis. [Brief description of the drawings]
[0014] [Figure 1a-c] This is a diagram showing the process of obtaining AMA1, ROP4, or ROP18 VLPs (Virus-like particles) by transfecting rBV (recombinant baculovirus) containing the AMA1, ROP4, or ROP18 gene, and rBV containing the influenza M1 gene into SF9 insect cells. [Diagram 2] 1 shows a timeline of an in vivo test process for obtaining infected serum from mice in one example of the present specification. [Diagram 3] FIG. 1 shows a schematic diagram of a method for diagnosing the VLPs produced in one example of the present specification using ELISA. [Figure 4]The specificity of AMA1-M1-VLPs for infected sera was confirmed by contacting sera from naive mice and mice infected with P. berghei ANKA (malaria parasite) or T. gondii (toxoplasma) ME49 with immunoplates coated with TLA (RH Tachyzoite lysate antigen), AMA1-M1-VLPs, and AMA1 protein, respectively. [Diagram 5] The sensitivity of AMA1-M1-VLPs to infected sera from mice infected with T. gondii ME49 was confirmed by contacting the sera with immunoplates coated with TLA, AMA1-M1-VLPs, and AMA1 protein, respectively. [Figure 6] The sensitivity of AMA1-M1-VLPs to human serum infected with T. gondii ME49 was confirmed by contacting the serum with immunoplates coated with TLA, AMA1-M1-VLPs, and AMA1 protein, respectively. [Figure 7] The specificity of ROP4-M1-VLPs for infected sera was confirmed by contacting sera from naive mice, mice infected with P. berghei ANKA, or T. gondii ME49 with immunoplates coated with TLA, ROP4-M1-VLPs, and ROP4 protein, respectively. [Figure 8] The sensitivity of ROP4-M1-VLPs to infected sera from mice infected with T. gondii ME49 was confirmed by contacting the sera with immunoplates coated with TLA, ROP4-M1-VLPs, and ROP4 protein, respectively. [Figure 9] The sensitivity of ROP4-M1-VLPs to human serum infected with T. gondii ME49 was confirmed by contacting the serum with immunoplates coated with TLA, ROP4-M1-VLPs, and ROP4 protein, respectively. [Figure 10]The specificity of ROP18-M1-VLPs for infected sera was confirmed by contacting sera from naive mice and mice infected with P. berghei ANKA or T. gondii ME49 with immunoplates coated with TLA, ROP18-M1-VLPs, and ROP18 protein, respectively. [Figure 11] The sensitivity of ROP18-M1-VLPs to the infected sera was confirmed by contacting the sera from mice infected with T. gondii ME49 with immunoplates coated with TLA, ROP18-M1-VLPs, and ROP18 protein, respectively. [Figure 12] The sensitivity of ROP18-M1-VLPs to human serum infected with T. gondii ME49 was confirmed by contacting the serum with immunoplates coated with TLA, ROP18-M1-VLPs, and ROP18 protein, respectively. [Figure 13] The results are shown in Fig. 1. Immunoplates coated with TLA, AMA1-M1-VLPs, ROP4-M1-VLPs, and ROP18-M1-VLPs were contacted with naive mouse serum, mouse serum infected with T. gondii ME49, serum from mice inoculated with 10μg of influenza M1 VLPs, and serum from mice inoculated with 10μg of NA (neuraminidase) VLPs. As a result, it was confirmed that AMA1-M1-VLPs, ROP4-M1-VLPs, and ROP18-M1-VLPs are capable of multiplex diagnosis of toxoplasmosis and influenza virus. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] One aspect of the present invention provides a composition for multiplex diagnosis of toxoplasmosis and / or influenza virus, comprising a virus-like particle (VLP) comprising a surface antigen protein derived from Toxoplasma and influenza virus matrix protein 1 (M1).
[0016] The composition may be of use for simultaneous multiplex diagnosis of toxoplasmosis and influenza virus.
[0017] As used herein, the term "virus-like particle" (VLP) or "virus-like particles" (VLPs) refers to a non-infectious viral subunit with or without viral proteins. For example, the virus-like particle may be completely devoid of DNA or RNA genome. In one embodiment, the virus-like particle may be produced by genetic engineering methods and contains matrix protein (M1) from influenza virus as a structural protein (core protein). The virus-like particle of the present invention may be produced by genetic engineering methods in the absence of a separate causative infectious agent, i.e., Toxoplasma gondii.
[0018] The term "influenza virus matrix protein 1" (M1) as used herein refers to a structural protein of influenza virus, a matrix protein that forms a coat inside the lipid layer that is the influenza virus envelope. The influenza virus is classified into subtypes designated as A, B, and C. The influenza virus is covered with a layer of matrix protein (M1) that acts as a link between the core and the viral envelope to form an outer shape, and the M1 protein can be widely used as a structural protein in the development of influenza virus-like particles. The virus-like particles of the present specification include influenza virus matrix protein 1 (M1) as a structural protein, and in one embodiment, the M1 can have the amino acid sequence of SEQ ID NO: 1. The M1 can also be encoded by a nucleic acid sequence of SEQ ID NO: 5.
[0019] The surface antigen protein derived from Toxoplasma can be used in the present invention without particular limitation on its type, so long as it is a protein that can induce immune activity against Toxoplasma.
[0020] Specifically, the surface antigen proteins of the present specification may include various types of proteins derived from Toxoplasma, such as SAG1 (Membrane-associated surface antigen), SAG2, GRA1 (secreted dense-granule protein), GRA2, GRA4, GRA7, MIC1 (Microneme protein), MIC2, MIC4, MIC6, MIC7, MIC8, MIC9, MIC10, MIC11, ROP1, ROP2, ROP3, ROP4, ROP5, ROP6, ROP7, ROP8, ROP9, ROP10, ROP11, ROP12, ROP13, ROP14, ROP15, ROP16, ROP17, ROP18, M2AP (MIC2 associated protein), AMA1 (Plasmodium apical membrane antigen 1), and BAG1, and preferably include at least one of AMA1, ROP4, and ROP18.
[0021] In this case, the AMA1 may have the amino acid sequence of SEQ ID NO: 2. The ROP4 may have the amino acid sequence of SEQ ID NO: 3. The ROP18 may have the amino acid sequence of SEQ ID NO: 4.
[0022] In addition, the AMA1 may be encoded by the nucleic acid sequence of SEQ ID NO:6, the ROP4 may be encoded by the nucleic acid sequence of SEQ ID NO:7, and the ROP18 may be encoded by the nucleic acid sequence of SEQ ID NO:8.
[0023] Here, the antigen protein introduced onto the surface of the virus-like particle has higher antigenicity than purely isolated recombinant proteins and can therefore form effective neutralizing antibodies, making it useful as a composition for multiple diagnostics of toxoplasmosis and influenza viruses.
[0024] In the virus-like particle, the ratio of the Toxoplasma surface antigen protein and the influenza virus matrix protein 1 may be 5:1 to 1:5, or 3:1, 1:1, or 1:3. Preferably, the ratio is 3:1.
[0025] The virus-like particle may be produced by using a vector containing a gene encoding a surface antigen protein derived from Toxoplasma and a vector containing a gene encoding influenza virus matrix protein 1. Specifically, the virus-like particle may be produced by co-infecting a host cell with a recombinant baculovirus containing a gene encoding a surface antigen protein derived from Toxoplasma and a recombinant baculovirus containing a gene encoding influenza virus matrix protein 1.
[0026] In this case, the host cell can be an insect cell. The insect cells may be any cell that has been developed or is commercially available as a host system for gene expression, such as Spodoptera frugiperda SF21, SF9, Trichoplusia ni, Anticarsa gemmitalis, Bombyx mori, Estigmene acrea, Heliothis virescens, Leucania separata, Lymantria dispar, Malacasoma disstria, Mammestra brassicae, Manduca sexta, Plutella zylostella, Spodoptera exigua, and Spodoptera littorlis), but is not limited to one or more of the following. In one embodiment, SF9 cells were used.
[0027] In addition, during coinfection, a recombinant baculovirus containing a gene encoding a surface antigen protein derived from Toxoplasma and a recombinant baculovirus containing a gene encoding influenza virus matrix protein 1 can be used in a 3:1 ratio to produce virus-like particles.
[0028] In particular, the virus-like particles comprising the Toxoplasma surface antigen protein and influenza virus matrix protein 1 have excellent specificity and sensitivity, and can therefore be used to detect autoantibodies produced in individuals infected with Toxoplasma and / or influenza virus.
[0029] For example, the VLPs can be used to determine the presence or absence of anti-AMA1, anti-ROP4, or anti-ROP18 antibodies produced in an individual during infection with Toxoplasma, as well as the presence or absence of anti-M1 antibodies produced in an individual during infection with influenza virus.
[0030] In a specific experimental example of the present invention, it was confirmed that high sensitivity was observed when ELISA was performed using the VLPs and sera obtained from mice and human patients infected with Toxoplasma. The VLPs did not show significant antibody reaction to sera from mice infected with malaria parasite (P. berghei ANKA) or naive mice, and therefore it was confirmed that they can be used to diagnose individuals infected with Toxoplasma. In addition, even though the same ELISA experiment was performed, there was almost no antibody reaction to proteins such as TLA (RH Tachyzoite lysate antigen), AMA1, ROP4, and ROP18, even in sera from Toxoplasma-infected mice, compared to the VLPs, and therefore it was confirmed that the VLPs of the present invention have a more sensitive effect of diagnosing Toxoplasma infection than the case of using proteins derived from Toxoplasma or Toxoplasma lysate.
[0031] Furthermore, the VLPs can more efficiently diagnose the presence or absence of Toxoplasma gondii and influenza virus infections in individuals simultaneously infected with Toxoplasma gondii and influenza virus.
[0032] In specific experimental examples of the present invention, it was confirmed that the VLPs of the present invention showed significant antigen-antibody reactions not only with serum derived from mice infected with Toxoplasma, but also with serum derived from mice infected with influenza virus, and therefore it was confirmed that the VLPs can be useful for simultaneous multiple diagnosis of Toxoplasma and influenza virus.
[0033] In yet another aspect, the present invention provides a multiplex diagnostic kit for toxoplasmosis and / or influenza virus, comprising the above-mentioned Toxoplasma and / or influenza virus diagnostic composition, which may comprise a virus-like particle comprising a surface antigen protein derived from Toxoplasma and influenza virus matrix protein 1 (M1).
[0034] The diagnostic kit may also be a diagnostic kit for use in simultaneous multiple diagnosis of toxoplasmosis and influenza virus.
[0035] In this case, the toxoplasmosis and / or influenza virus diagnostic composition, the Toxoplasma-derived surface antigen protein, the influenza virus matrix protein, and the virus-like particle are as described above. As a specific example, the kit can be produced using AMA1-M1-VLPs, which are VLPs expressing the Toxoplasma AMA1 protein, ROP4-M1-VLPs, which are VLPs expressing the Toxoplasma ROP4 protein, and ROP18-M1-VLPs, which are VLPs expressing the Toxoplasma ROP18 protein. In this case, the VLPs can be present in the detection section of the diagnostic kit.
[0036] As used herein, the term "detection portion" refers to a portion including a support on which a VLP composition containing a Toxoplasma surface antigen protein is immobilized, and where the VLP composition specifically reacts with at least one of antibodies against Toxoplasma and antibodies against influenza virus.
[0037] The composition for multiple diagnosis of toxoplasmosis and / or influenza virus in the detection part is coated on a support (e.g., a nitrocellulose membrane) of the detection part using a dispenser device, and a biological sample isolated from an individual is contacted with the corresponding part to perform diagnosis of toxoplasmosis or multiple diagnosis of toxoplasmosis and influenza virus.
[0038] The diagnostic kit may be at least one selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA) kit, a radioimmunoassay (RIA) kit, a sandwich assay kit, a Western Blot kit, an immunoblot assay kit, and an immunohistochemical staining kit, but is not limited thereto.
[0039] In one embodiment, the diagnostic kit detects the presence or absence of IgG, IgA or IgM antibodies in a biological sample isolated from an individual to diagnose the presence or absence of Toxoplasma gondii and influenza virus infections, either individually or simultaneously, and the process may include, but is not limited to, at least one selected from the group consisting of enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), sandwich assay, Western blot, immunoblot assay, and immunohistochemical staining.
[0040] Yet another aspect of the present invention provides a method for providing information necessary for multiplex diagnosis of Toxoplasma and / or influenza virus infection, comprising the steps of contacting a biological sample isolated from an individual with a toxoplasmosis and / or influenza virus multiple diagnostic composition comprising a virus-like particle comprising a surface antigen protein derived from Toxoplasma and influenza virus matrix protein 1, and detecting antibodies that bind to the virus-like particle.
[0041] In this case, the toxoplasmosis and / or influenza virus diagnostic composition, the Toxoplasma-derived surface antigen protein, the influenza virus matrix protein, and the virus-like particle are as described above. In addition, the term "biological sample isolated from an individual" as used herein preferably refers to a body fluid secreted outside the body, including blood, serum, plasma, urine, tears, saliva, milk, etc., and more preferably blood obtained from an individual, but is not limited thereto. In this case, the individual may be a mammal such as a dog, a cat, or a human, and preferably a human.
[0042] The step of detecting antibodies bound to the virus-like particles may include at least one selected from the group consisting of Enzyme-linked immunosorbent assay (ELISA), Radioimmunoassay (RIA), Sandwich assay, Western Blot, Immunoblot assay, and Immunohistochemical staining.
[0043] The method for detecting the antibody bound to the virus-like particle may be a method for detecting an antigen-antibody reactant or a labeling agent. Depending on the type of the antigen-antibody reactant or labeling agent, a method known to those skilled in the art may be used, specifically, the naked eye, a detection device, a detection reagent, etc. may be used. The detection device may be a confocal laser scanner, and the detection reagent may include a predetermined labeled reagent, an auxiliary specific binding member, and / or a component of a signal generating system that allows the presence of the analyte to be tested to be externally identified through the naked eye or other instruments. The detection reagent for the label is already well known to those skilled in the art to which the present invention pertains.
[0044] Such label forms include catalysts, enzymes (e.g., phosphatase, peroxidase, etc., more specific examples of which include basic phosphatase and horseradish peroxidase used in combination with an enzyme substrate), enzyme substrates (e.g., nitroblue tetrazolium, 3,5',5,5'-tetranitrobenzidine, 4-methoxy-1-naphthol, 4-chloro-1-naphthol, 5-bromo-4-chloro-3-indole phosphate, dioxetanes as chemiluminescent enzyme substrates, and derivatives and analogs thereof), fluorescent compounds (e.g., fluorescein, phycobiliprotein, rhodamine, etc., and derivatives and analogs thereof), chemiluminescent compounds, metal sols, dye sols, particulate latex, color indicators, colored substances contained in liposomes, and the like. matter), carbon sols, and non-metallic sols such as selenium.
[0045] Yet another aspect of the present invention provides a method for multiplex diagnosis of Toxoplasmosis and / or influenza virus infection, comprising the steps of contacting a biological sample isolated from an individual with the above-mentioned toxoplasmosis and / or influenza virus diagnostic composition and detecting antibodies that bind to the virus-like particles.
[0046] Yet another aspect of the present invention provides a use of a virus-like particle comprising a surface antigen protein from Toxoplasma and influenza virus matrix protein 1 (M1) for diagnosing toxoplasmosis and / or influenza virus infection, specifically for diagnosing toxoplasmosis or for simultaneously multiplexing diagnosis of toxoplasmosis and influenza virus.
[0047] The present invention will be described in more detail with reference to the following examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention and should not be construed as limiting the scope of the present invention.
[0048] I. Production of VLPs Containing Toxoplasma and Influenza Antigens
[0049] Production Example 1. Production of baculovirus expressing Toxoplasma antigen
[0050] Example 1.1. Obtaining Toxoplasma cDNA
[0051] To extract RNA coding for AMA1, ROP4, and ROP18 from Toxoplasma RH, RNA was obtained from Toxoplasma RH samples. Then, RT-PCR was performed on the extracted antigen RNA to obtain cDNA derived from Toxoplasma. Then, dsDNA was obtained based on the obtained cDNA.
[0052] Example 1.2. Obtaining antigen cDNA
[0053] To perform PCR for the target genes, primers for amplifying AMA1, ROP4, and ROP18 were designed and ordered. Distilled water was added to a mixture of 0.25 μL of PCR enzyme TaKaRa Ex TaqTM, 5 μL of 10X Ex Taq buffer, 4 μL of dNTP mixture, 1 μL of template, 2 μL of forward primer, and 2 μL of reverse primer to a total volume of 50 μL. Then, PCR was performed at 98°C for 10 seconds, 55°C for 30 seconds, and 72°C for 1 minute for 30 to 40 cycles. Then, the PCR amplified products diluted with DNA markers and loading dye (6x) were loaded onto an agarose gel. Then, the PCR amplified products were confirmed using UV or other methods. Then, antigen-encoding DNA was extracted from the gel where the desired gene was located.
[0054] In the above, for the AMA1 gene, 5'-AAAGAATTCACCATGGGGCTCGTGGGCGTACA-3' (sequence number 11) was used as the forward primer and 5'-TTACTCGAGCTAGTAATCCCCCTCGACCA-3' (sequence number 12) was used as the reverse primer, for the ROP4 gene, 5'-AAAGCATGCACCATGGGGCACCCTACCTCTTT-3' (sequence number 13) was used as the forward primer and 5'-TTAGGTACCTCACGTTTCCGGTGGTGGCAT-3' (sequence number 14) was used as the reverse primer, and for the ROP18 gene, 5'-AAAGGATCCACCATGTTTTCGGTACAGCGGCC-3' (sequence number 15) was used as the forward primer and 5'-TTATCTAGATTATTCTGTGTGGAGATGTTC-3' (sequence number 16) was used as the reverse primer.
[0055] Example 1.3. Amplification of antigen gene
[0056] The DNA of Toxoplasma antigens AMA1, ROP4, and ROP18 extracted in Preparation 1.2 was loaded into a TA vector. The TA vector loaded with the antigen genes was then transformed into E. coli cells and cultured. The transformed E. coli cells were cultured, and the genes encoding AMA1, ROP4, and ROP18 were obtained.
[0057] Preparation example 1.4. Preparation of pFast-Bac plasmid carrying antigen gene
[0058] The AMA1, ROP4, and ROP18 antigen genes obtained in Preparation 1.3 were each loaded into the pFast-Bac vector. The pFast-Bac vectors loaded with the antigen genes were transformed into DH10B cells. The transformed cells were cultured to obtain a large amount of pFast-Bac vectors loaded with the antigen genes.
[0059] Production Example 1.5. Production of baculovirus expressing Toxoplasma antigen
[0060] The pFast-Bac vectors carrying AMA1, ROP4, and ROP18 DNA were transfected into SF9 cells using cellfectin II (Invitrogen, USA). Recombinant baculoviruses (rBVs) expressing AMA1, ROP4, and ROP18 were produced using the Bac-to-Bac expression system (Invitrogen) according to the manufacturer's instructions.
[0061] In addition, rBV expressing influenza virus M1 was prepared in the same manner as above, where the M1 gene was amplified by RT-PCR using the forward primer 5'-AAAGGATCCACCATGAGTCTTCTAACCGAGGT-3' (SEQ ID NO: 9) and the reverse primer 5'-TTACTCGAGTTACTCTAGCTCTATGTTGAC-3' (SEQ ID NO: 10).
[0062] Example 1. Production of VLPs containing Toxoplasma antigens and influenza antigens: AMA1-M1-VLPs
[0063] To prepare the first Toxoplasma VLP containing AMA1 and M1 proteins, SF9 cells were co-infected with the AMA1 rBV and M1 rBV prepared in Preparation Example 1. The ratio of M1 rBV to AMA1 antigen rBV was 1:3. The infected SF9 cells were then cultured, and harvested when the death rate of SF9 cells reached 30% to 40%. Specifically, the cultured cells and the culture medium were centrifuged at 6,000 rpm for 30 minutes to collect the supernatant, and then centrifuged at 30,000 rpm at 4°C for 30 minutes to pellet the cells. The VLPs were purified through a sucrose gradient. The VLPs were resuspended in phosphate-buffered saline (PBS) until use. The VLPs expressing the AMA1 antigen and M1 antigen were named AMA1-M1-VLPs. An example of the process of preparing AMA1-M1-VLPs is illustrated in FIG. 1a.
[0064] Example 2. Production of VLPs containing Toxoplasma antigens and influenza antigens: ROP4-M1-VLPs
[0065] In addition, to prepare a second Toxoplasma VLP containing ROP4 and M1 proteins, SF9 was co-infected with the ROP4 rBV and M1 rBV prepared in Preparation Example 1 in the same manner as in Example 1 to obtain ROP4-M1-VLPs (Figure 1b).
[0066] Example 3. Production of VLPs containing Toxoplasma antigens and influenza antigens: ROP18-M1-VLPs
[0067] In addition, to prepare a third Toxoplasma VLP containing ROP18 and M1 proteins, SF9 was co-infected with the ROP18 rBV and M1 rBV prepared in Preparation Example 1 in the same manner as in Example 1 to obtain ROP18-M1-VLPs (Figure 1c).
[0068] II. Diagnosis of Toxoplasma gondii and influenza using VLPs
[0069] Example 2. Collect serum from mice infected with Toxoplasma and Malaria
[0070] Seven-week-old female BALB / C mice were orally infected with 300 cysts / mouse (hd) of Toxoplasma gondii (ME49 strain), and infected serum was obtained by collecting blood from the orbital plexus and centrifuging it. An exemplary procedure for the in vivo process is shown in FIG. 2. In addition, 0.5% (0.5×10 4 ) and then serum was collected from the infected mice.
[0071] Experimental Example 1. AMA1-M1-VLPs and IgG antibody reaction test
[0072] In order to confirm whether the AMA1-M1-VLPs of the present invention obtained through Example 1 can actually diagnose individuals infected with Toxoplasma, ELISA was used to confirm whether AMA1-M1-VLPs react with Toxoplasma-specific antibodies in the serum of mice and human patients infected with Toxoplasma (Experimental Examples 1.1 to 1.3).
[0073] Experimental Example 1.1. Specificity test of AMA1-M1-VLPs and IgG antibody reaction in mouse serum
[0074] AMA1-M1-VLPs, AMA1 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 1 were coated on a 96-well immunoplate at a concentration of 4 μg / mL. The TLA refers to the lysate antigen of the tachyzoite stage of Toxoplasma RH life cycle. Then, 14 mouse sera infected with malaria parasites (P. berghei ANKA) and 14 mouse sera infected with T. gondii ME49 300 cysts were diluted 100-fold and ELISA was performed (Figure 3). Serum from mice not infected with malaria parasites or Toxoplasma was used as a control group (Naive).
[0075] As a result, among the three types of coated antigens, the TLA and AMA1 protein antigens did not react with any of the sera. In contrast, the AMA1-M1-VLPs showed little reaction with naive sera and sera infected with malaria parasites, but showed high reactivity only with sera infected with Toxoplasma, confirming the specificity between the AMA1-M1-VLPs and Toxoplasma-specific IgG antibodies in the sera (Figure 4).
[0076] Experimental Example 1.2. Sensitivity test of AMA1-M1-VLPs and IgG antibody reaction in mouse serum
[0077] In Experimental Example 1.1, it was confirmed that AMA-M1-VLPs specifically binds to Toxoplasma-specific IgG antibodies, and in order to confirm the sensitivity of these reactions, the same experiment as in Experimental Example 1.1 was performed by treating serum containing the IgG antibodies at various concentrations. The AMA1-M1-VLPs, AMA1 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 1 were each coated on a 96-well immunoplate at a concentration of 4 μg / mL. Then, 14 mouse serum samples infected with T. gondii ME49 300 cysts were diluted 100-fold, 300-fold, and 900-fold, respectively, and ELISA was performed (Figure 3). Serum from mice not infected with Toxoplasma was used as a control group (Naive).
[0078] As a result, similar to Experimental Example 1.1, AMA1-M1-VLPs was shown to have the highest specificity for mouse serum containing Toxoplasma-specific IgG, and it was confirmed that it was most sensitive to serum diluted 100 times (Figure 5).
[0079] Experimental Example 1.3. Sensitivity test of AMA1-M1-VLPs and IgG antibody reaction in human serum
[0080] To confirm the sensitivity of the antibody response to human serum infected with Toxoplasma, experiments were performed in a similar manner to Experimental Examples 1.1 and 1.2. The AMA1-M1-VLPs, AMA1 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 1 were each coated on a 96-well immunoplate at a concentration of 4 μg / mL. Then, 10 serum samples from patients infected with T. gondii were diluted 100-fold, 300-fold, and 900-fold, respectively, and ELISA was performed (Figure 3). Serum from mice not infected with Toxoplasma was used as a control group (Naive).
[0081] As a result, similar to the experiments using mouse serum, AMA1-M1-VLPs were shown to have the highest specificity for human serum containing Toxoplasma-specific IgG, and it was confirmed that it was most sensitive to serum at a concentration 100 times diluted (Figure 6).
[0082] Experimental Example 2. ROP4-M1-VLPs and IgG antibody reaction test
[0083] As in Experimental Example 1, in order to confirm whether the ROP4-M1-VLPs of the present invention obtained through Example 2 can actually diagnose individuals infected with Toxoplasma, ELISA was used to confirm whether ROP4-M1-VLPs react with Toxoplasma-specific antibodies in the serum of mice and human patients infected with Toxoplasma (Experimental Examples 2.1 to 2.3).
[0084] Experimental Example 2.1. Specificity test of ROP4-M1-VLPs and IgG antibody reaction in mouse serum
[0085] The ROP4-M1-VLPs, ROP4 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 2 were each coated on a 96-well immunoplate at a concentration of 4 μg / mL. Then, 14 mouse sera infected with malaria parasites (P. berghei ANKA) and 14 mouse sera infected with T. gondii (Toxoplasma) ME49 300 cysts were diluted 100-fold for ELISA (Figure 3). Sera from mice not infected with malaria parasites or Toxoplasma were used as a control group (Naive).
[0086] As a result, among the three types of coated antigens, the TLA and AMA1 protein antigens did not react with any of the sera. In contrast, ROP4-M1-VLPs showed little reaction with naive sera and sera infected with malaria parasites, but showed high reactivity only with sera infected with Toxoplasma, confirming the specificity between ROP4-M1-VLPs and Toxoplasma-specific IgG antibodies in the sera (Figure 7).
[0087] Experimental Example 2.2. Sensitivity test of ROP4-M1-VLPs and IgG antibody reaction in mouse serum
[0088] In Experimental Example 2.1, it was confirmed that ROP4-M1-VLPs specifically binds to Toxoplasma-specific IgG antibodies, and in order to confirm the sensitivity of these reactions, the same experiment as in Experimental Example 2.1 was performed by treating serum containing the IgG antibodies at various concentrations. The ROP4-M1-VLPs, ROP4 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 2 were each coated on a 96-well immunoplate at a concentration of 4 μg / mL. Then, 14 mouse serum samples infected with T. gondii ME49 300 cysts were diluted 100-fold, 300-fold, and 900-fold, respectively, and ELISA was performed (Figure 3). Serum from mice not infected with Toxoplasma was used as a control group (Naive).
[0089] As a result, similar to Experimental Example 2.1, ROP4-M1-VLPs were shown to have the highest specificity for mouse serum containing Toxoplasma-specific IgG, and it was confirmed that it was most sensitive to a concentration diluted 100 times (Figure 8).
[0090] Experimental Example 2.3. Sensitivity test of ROP4-M1-VLPs and IgG antibody reaction in human serum
[0091] To confirm the sensitivity of the antibody response to human serum infected with Toxoplasma, experiments were performed in a similar manner to Experimental Examples 2.1 and 2.2. The ROP4-M1-VLPs, ROP4 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 2 were each coated on a 96-well immunoplate at a concentration of 4 μg / mL. Then, 10 serum samples from patients infected with T. gondii were diluted 100-fold, 300-fold, and 900-fold, respectively, and ELISA was performed (Figure 3). Serum from mice not infected with Toxoplasma was used as a control group (Naive).
[0092] As a result, similar to the experiments using mouse serum, AMA1-M1-VLPs were shown to have the highest specificity for human serum containing Toxoplasma-specific IgG, and it was confirmed that it was most sensitive to serum at a concentration 100 times diluted (Figure 9).
[0093] Experimental Example 3. ROP18-M1-VLPs and IgG antibody reaction test
[0094] As in Experimental Example 1, in order to confirm whether the ROP18-M1-VLPs of the present invention obtained through Example 3 can actually diagnose individuals infected with Toxoplasma, ELISA was used to confirm whether ROP18-M1-VLPs react with Toxoplasma-specific antibodies in the serum of mice and human patients infected with Toxoplasma (Experimental Examples 3.1 to 3.3).
[0095] Experimental Example 3.1. Specificity test of ROP18-M1-VLPs and IgG antibody reaction in mouse serum
[0096] The ROP18-M1-VLPs, ROP18 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 3 were coated on a 96-well immunoplate at a concentration of 4 μg / mL. Then, 14 mouse sera infected with malaria parasites (P. berghei ANKA) and 14 mouse sera infected with T. gondii (Toxoplasma) ME49 300 cysts were diluted 100-fold to perform ELISA (Figure 3). Serum from mice not infected with malaria parasites or Toxoplasma was used as a control group (Naive). As a result, among the three types of coated antigens, TLA and AMA1 protein antigens did not react with any of the sera. In contrast, ROP18-M1-VLPs showed little reaction with naive sera and sera infected with malaria parasites, but showed high reactivity only with sera infected with Toxoplasma, confirming the specificity between ROP18-M1-VLPs and Toxoplasma-specific IgG antibodies in the sera (Figure 10).
[0097] Experimental Example 3.2. Sensitivity test of ROP18-M1-VLPs and IgG antibody reaction in mouse serum
[0098] In Experimental Example 3.1, it was confirmed that ROP18-M1-VLPs specifically binds to Toxoplasma-specific IgG antibodies, and in order to confirm the sensitivity of these reactions, the same experiment as in Experimental Example 3.1 was performed by treating serum containing the IgG antibodies at various concentrations. The ROP18-M1-VLPs, ROP18 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 3 were each coated on a 96-well immunoplate at a concentration of 4 μg / mL. Then, 14 mouse serum samples infected with T. gondii ME49 300 cysts were diluted 100-fold, 300-fold, and 900-fold, respectively, and ELISA was performed (Figure 3). Serum from mice not infected with Toxoplasma was used as a control group (Naive).
[0099] As a result, similar to Experimental Example 3.1, ROP18-M1-VLPs were shown to have the highest specificity for mouse serum containing Toxoplasma-specific IgG, and it was confirmed that it was most sensitive to serum diluted 100 times (Figure 11).
[0100] Experimental Example 3.3. Sensitivity test of ROP18-M1-VLPs and IgG antibody reaction in human serum
[0101] To confirm the sensitivity of the antibody response to human serum infected with Toxoplasma, experiments were performed in a similar manner to Experimental Examples 3.1 and 3.2. The ROP18-M1-VLPs, ROP18 protein, and TLA (RH Tachyzoite lysate antigen) obtained in Example 3 were each coated on a 96-well immunoplate at a concentration of 4 μg / mL. Then, 10 sera from patients infected with T. gondii were diluted 100-fold, 300-fold, and 900-fold, respectively, and ELISA was performed (Figure 3). Serum from mice not infected with Toxoplasma was used as a control group (Naive).
[0102] As a result, similar to the experiments using mouse serum, AMA1-M1-VLPs were shown to have the highest specificity for human serum containing Toxoplasma-specific IgG, and it was confirmed that it was most sensitive to serum at a concentration 100 times diluted (Figure 12).
[0103] Experimental Example 4. Simultaneous diagnosis of Toxoplasma gondii and influenza using AMA1-M1-VLPs, ROP4-M1-VLPs, and ROP18-M1-VLPs
[0104] AMA1-M1-VLPs, ROP4-M1-VLPs, ROP18-M1-VLPs, and TLA (RH Tachyzoite lysate antigen) obtained in Examples 1 to 3 were each coated on a 96-well immunoplate at a concentration of 4 μg / mL.
[0105] Then, ELISA was performed using naive mouse serum, mouse serum infected with T. gondii ME49 300 cysts, serum from mice inoculated with 10 μg of influenza M1 VLPs, and serum from mice inoculated with 10 μg of NA (neuraminidase) VLPs, which were diluted 100-fold.
[0106] Here, NA VLPs were produced by amplifying NA cDNA in influenza virus A / PR / 8 / 34 (H1N1) and using the same method as that for producing T. gondii VLPs.
[0107] As a result, among the four types of antigen-coated immunoplates, the immunoplates coated with AMA1-M1-VLPs, ROP4-M1-VLPs, and ROP18-M1-VLPs showed significantly high IgG antibody responses in the serum of mice infected with Toxoplasma when the OD value was measured at 492 nm. Moreover, the OD value was measured to be 0.2 or more for the serum of mice inoculated with 10 μg of influenza M1 VLPs or NA VLPs at the same time, confirming that the immunoplates coated with AMA1-M1-VLPs, ROP4-M1-VLPs, and ROP18-M1-VLPs are capable of multiple diagnosis of toxoplasmosis and influenza virus (FIG. 13).
[0108] In conclusion, it was confirmed that AMA1-M1-VLPs, ROP4-M1-VLPs, and ROP18-M1-VLPs can detect anti-AMA1 antibodies, anti-ROP4 antibodies, and / or anti-ROP18 antibodies present in the serum of individuals infected with Toxoplasma with high sensitivity and specificity, as well as anti-M1 antibodies present in the serum of individuals infected with influenza virus with high sensitivity and specificity. Therefore, the AMA1-M1-VLPs, ROP4-M1-VLPs, and ROP18-M1-VLPs of the present application can be used as a composition for simultaneously diagnosing individuals infected with Toxoplasma and / or individuals infected with influenza virus.
Claims
1. A composition for multiple diagnosis of toxoplasmosis and / or influenza virus, comprising a virus-like particle comprising a surface antigen protein derived from Toxoplasma and influenza virus matrix protein 1 (M1), wherein the surface antigen protein derived from Toxoplasma is at least one selected from the group consisting of AMA1 and ROP18.
2. The toxoplasmosis and / or influenza virus multiple diagnostic composition according to claim 1, wherein the virus-like particle further comprises a surface antigen protein ROP4 derived from Toxoplasma.
3. The composition for multiple diagnosis of toxoplasmosis and / or influenza viruses according to claim 1, wherein M1 has the amino acid sequence of SEQ ID NO:
1.
4. The AMA1 has the amino acid sequence of SEQ ID NO:2, The ROP4 has the amino acid sequence of SEQ ID NO:3, The composition for multiple diagnosis of toxoplasmosis and / or influenza viruses according to claim 2 , wherein the ROP18 has the amino acid sequence of SEQ ID NO:
4.
5. The composition for multiple diagnosis of toxoplasmosis and / or influenza virus according to claim 1, wherein in the virus-like particle, the ratio of the surface antigen protein derived from Toxoplasma to influenza virus matrix protein 1 is 3:
1.
6. The composition for multiple diagnosis of toxoplasmosis and / or influenza viruses according to claim 1, wherein the virus-like particle is produced by co-infecting a recombinant baculovirus containing a gene encoding a surface antigen protein derived from Toxoplasma and a recombinant baculovirus containing a gene encoding influenza virus matrix protein 1.
7. The composition for multiple diagnosis of toxoplasmosis and / or influenza virus according to claim 5, characterized in that during coinfection, a recombinant baculovirus containing a gene encoding a surface antigen protein derived from Toxoplasma and a recombinant baculovirus containing a gene encoding influenza virus matrix protein 1 are infected in a ratio of 3:
1.
8. The composition for multiplex diagnosis of toxoplasmosis and / or influenza virus according to claim 1, characterized in that it is used to diagnose the level of autoantibodies in an individual infected with toxoplasmosis and / or influenza virus.
9. A Toxoplasma and / or influenza virus multiplex diagnostic kit comprising the composition of any one of claims 1 to 8.
10. 10. The Toxoplasma and influenza virus multiple diagnostic kit according to claim 9, wherein the diagnostic kit is any one selected from the group consisting of an enzyme-linked immunosorbent assay (ELISA) kit, a radioimmunoassay (RIA) kit, a sandwich assay kit, a Western Blot kit, an immunoblot assay kit, and an immunohistochemical staining kit.
11. contacting a biological sample isolated from an individual with a toxoplasmosis and / or influenza virus multi-diagnostic composition comprising a virus-like particle comprising a surface antigen protein from Toxoplasma and influenza virus matrix protein 1; detecting antibodies that bind to the virus-like particles; The surface antigen protein derived from Toxoplasma is at least one selected from the group consisting of AMA1 and ROP18. A method for providing the information required for multiplex diagnosis of Toxoplasma gondii and / or influenza virus infection.
12. The method for providing information required for multiple diagnosis of Toxoplasma and / or influenza virus infection according to claim 11, wherein the virus-like particle further comprises a surface antigen protein ROP4 derived from Toxoplasma.
Citation Information
Patent Citations
Human papillomavirus multiple assay
JP2005524076A
Monoclonal antibodies that bind to avian influenza virus subtype h5 hemagglutinin and their uses
JP2009524434A
Recombinant virus-like particles encoded by multiple gene vectors
JP2012525133A
Utilization of recombinant influenza viruses and modified vaccinia ankara virus (MVA) with genes that encode for the toxoplasma gondii SAG1 and SAG2 surface proteins, as vaccines against toxoplasmosis
US20110045016A1
